ORCA Therapeutics B.V. is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents (ORCA).

These agents are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells,
while healthy cells are left unharmed. In addition, oncolytic viruses are used as efficient delivery agents to express anti-cancer products at high levels in cancer cells and as anti-cancer vaccines that present cancer antigens to the immune system.

 
 

News

22 - 23 May 2012
ORCA Therapeutics presenting at the World Gene Therapy Congress Europe

read more +

 

8 November 2011
ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government

read more +

 

Job Opportunities

18 August 2010
Technician R&D

read more +
 

   

Terms of use | Disclaimer | Contact

© 2009 ORCA Therapeutics B.V. | Photography: Wen L. Dong, PhD